Artelo Biosciences, Inc.

NASDAQ: ARTL · Healthcare · Biotechnology

PublicHQ Solana Beach, CA · San DiegoCIK 0001621221Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 30DQ —GM —SS 30

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, Piotroski F · ↓ return on assets, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$12.9M

Employees

as of 2026-09-22

Market cap

$1.6M

as of 2026-09-22

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$12.9M-$12.9M2025

Operating income-$11.4M-$11.4M2025

Total assets$2.8M$2.8M2025

Liabilities$4.1M$4.1M2025

Equity-$1.3M-$1.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Artelo Biosciences, Inc.’s financial profile?

Artelo Biosciences, Inc. earned -$12.9M in FY2025 net income.

Peers · Healthcare

TransCode Therapeutics, Inc.——Restart Life Sciences Corp.——Algernon Pharmaceuticals Inc.——Stemsation International, Inc.——Kelyniam Global, Inc.——Endovia Health Sciences, Inc.——

Neighbors

San Diego →

QUALCOMM Incorporated$44.3B79B+Realty Income Corporation$5.7B61C Sempra$12.4B63C DexCom, Inc.$4.7B87A ResMed Inc.$5.1B——Illumina, Inc.$4.3B84B+

Key facts

CEOGregory D. Gorgas

SectorHealthcare

IndustryBiotechnology

HeadquartersSolana Beach, CA

ExchangeNASDAQ: ARTL

Employees7

IPO date2019-06-21

Latest filings

8-K2026-08-27 10-Q2026-08-12 8-K2026-07-17 DEF 14A2026-06-05 8-K2026-05-27 8-K2026-05-15 10-Q2026-05-14 8-K2026-04-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.